The DOI matches its Crossref record; 121 of the 122 references it cites were found in a registry or an index; none of the 197 sources its claims cite is checked for support yet.
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
Open accessAbstract
INTRODUCTION: GLP-1-based therapies have changed the treatment of overweight/obesity. Liraglutide 3.0 mg daily, the first GLP-1 RA approved for treatment of overweight, induced a weight loss of 6-8%, Semaglutide 2.4 mg once weekly improved weight loss to about 12-15%, while the dual GIP/GLP-1 receptor agonist tirzepatide once weekly has induced a weight loss of about 20% in obese people without diabetes. AREAS COVERED: This review describes results obtained with GLP-1 mono-agonists, GLP-1/GIP dual agonists, GLP-1/glucagon co-agonists, and the triple agonist retatrutide (GIP/GLP-1/glucagon), which have shown beneficial effect both on body weight and steatotic liver disease. A combination of semaglutide (a GLP-1 agonist) and cagrilintide (a long-acting amylin analogue) for weekly administration is currently in phase III development, and so is oral semaglutide and several non-peptide small molecule GLP-1 agonists for oral administration. The adverse events with the GLP-1-based therapies are primarily gastrointestinal and include nausea, vomiting, obstipation, or diarrhea, which often can be mitigated by slow up titration. EXPERT OPINION: The GLP-1-based therapies will change the treatment of obesity and its comorbidities including steatotic liver disease in the future. Outstanding question is maintenance of the weight loss, possibly pharmacological treatment needs to be life-long.
Overview
CoChat Summary
TL;DR
This narrative review summarizes phase 2/3 GLP-1-based obesity therapies, from liraglutide and semaglutide to dual/triple agonists such as tirzepatide, CagriSema, and retatrutide. It concludes these agents will change obesity and comorbidity treatment, but long-term maintenance, safety, cost, and lean-mass loss remain unresolved.
Key findings
- Established GLP-1-based therapies produce escalating weight loss: liraglutide 3.0 mg induced 6–8%, semaglutide 2.4 mg about 12–15% (STEP 1: −14.9% vs −2.4% placebo at 68 weeks), and tirzepatide about 20% (SURMOUNT-1: −20.9% with 15 mg vs −3.1% placebo at 72 weeks).
- In REDEFINE 1, CagriSema 2.4 mg produced −22.7% weight loss at 68 weeks vs −16.1% for semaglutide 2.4 mg, −11.8% for cagrilintide 2.4 mg, and −2.3% for placebo.
- Retatrutide, a GIP/GLP-1/glucagon triple agonist, led to up to −24.2% weight loss at 48 weeks in a phase 2 trial (12 mg vs −2.1% placebo) and reduced liver fat by up to −86.0% at 48 weeks in a substudy.
- Oral agents showed meaningful effects: oral semaglutide 50 mg gave −15.1% vs −2.4% placebo at 68 weeks; orforglipron gave −9.4% to −14.7% vs −2.3% placebo at 36 weeks; danuglipron phase 2b reached up to −13% vs −1.4% placebo at 32 weeks but with >50% discontinuation across doses.
Methods
- Narrative review of GLP-1-based anti-obesity drugs, with a systematic literature search of published articles, reference lists, EASD/ADA abstract programs from the last 5 years, and pharmaceutical company press releases; focus on randomized controlled trials and English-language publications.
- Data are drawn from phase 2/3 trials and press releases for liraglutide, semaglutide, tirzepatide, amylin analogues, dual GLP-1/GIP, GLP-1/glucagon, GLP-1/FGF-21, and triple agonists.
- Main analysis is a narrative synthesis of body weight, glycemic, liver, cardiovascular, and adverse-event outcomes rather than a formal meta-analysis.
Limitations
- The paper states limitations of GLP-1-based therapy: high cost, loss of lean body mass, gastrointestinal adverse events, and weight regain after stopping; long-term safety data are missing, with the longest placebo-controlled trial about 4 years.
- The paper notes that data for newer GLP-1/glucagon agonists and GIP/GLP-1/glucagon triple agonists come primarily from short-term phase 2 studies with few participants, and individual weight-loss response cannot currently be predicted.
- Evident from the text: several pipeline results rely on press releases or abstract presentations, and the review does not describe a formal risk-of-bias assessment or quantitative meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 9 Not valid · 179 Not checked · 40 Own results and interpretations
None of the sources cited for this claim have been checked yet.
In the paper
“Weight loss was greater with liraglutide (−6.1% vs −1.9%) than with placebo.”
§ 3. Single GLP-1 RAs > 3.1. Liraglutide
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“After 56 weeks, the weight loss was − 8% in the liraglutide group compared with − 2.6% in the placebo group”
§ 3. Single GLP-1 RAs > 3.1. Liraglutide
What the sources say
- Not matchedcites [Citation17]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Liraglutide 3.0 mg daily, the first GLP-1 RA approved for treatment of overweight, induced a weight loss of 6–8%”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“After 68 weeks the reduction in BMI was −13.9% with semaglutide 2.4 mg and −2.7% with placebo [Citation38].”
§ 3. Single GLP-1 RAs > 3.1. Liraglutide
What the sources say
- Not matchedcites [Citation38]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“The mean weight losses were −15.8%, −6.4% and −1.9%, respectively.”
§ 3. Single GLP-1 RAs > 3.1. Liraglutide
What the sources say
- Not matchedcites [Citation33]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
106 more claims
Create a free account to see all 228 claims and every source verdict.
- Probably not a substantial claim. 55
- The quote only partly states this claim. 3
- It may state two separate claims as one. 75
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ 3. Single GLP-1 RAs > 3.1. Liraglutide
“An improvement in fibrosis stage occurred in 43% in the 2.4 mg group and in 33% in the placebo group.”
§ 3. Single GLP-1 RAs > 3.1. Liraglutide
“In a placebo-controlled phase 2 trial, the effect of semaglutide 0.1, 0.2 and 0.4 mg OD over 72 weeks was investigated in participant with biopsy verified metabolic dysfunction-associated steatotic liver disease (MASLD) [Citation42].”
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855 · cited 1×
“Obesity is associated with an increased risk of the metabolic syndrome, type 2 diabetes, cardiovascular diseases, skeletal and muscle pains, liver diseases and cancer as well as psychiatric diseases [3].”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“In SURMOUNT 1, 2539 participants were randomized to tirzepatide 5, 10, 15 mg once weekly for 72 weeks, including a 20-week dose escalating period [82].”
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 3×
“GLP-1 RAs reduce the rates of Major Cardiovascular Events (MACE), heart failure, and elicit significant improvements of MASLD, kidney disease and reduce low grade inflammation [13,44].”
InfluentialA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 2×
“In the SCALE-1 Obesity and Prediabetes study with a duration of initially 56 weeks, 3731 subjects were included, 2285 of whom had prediabetes [17].”
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099 · cited 1×
“…study in people ( n = 3533) with type 2 diabetes and chronic kidney disease, (Table 2) the weight loss was −5.6% and −1.5% with semaglutide 2.4 mg and placebo, respectively, and semaglutide reduced the risk of clinical important kidney outcome and cardiovascular death compared with placebo [51].”
InfluentialA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 2×
“The reduction in liver fat was about 47% after 52 weeks with tirzepatide, and approximately 50% with semaglutide after 52 weeks [42,76,130].”
InfluentialSemaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 1×
“%) was assessed in a trial including 529 participants with a median BMI of 37 kg/m 2 [46,47].”
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“In the phase 3 program with 1 mg of semaglutide in people with type 2 diabetes, the mean weight loss was about − 5% to − 6% and reduction in HbA1c was about 1.6% (18 mmol/mol) [26].”
Influential
Research works printed but not linked: 13
- Press release novo nordisk A/S 17. 2025 Jan.
- Semaglutide 2.4 mg demonstrated superior improvement in liver fibrosis and MASH resolution in the ESSENCE trial. Press release novo nordisk A/S 1. 2024 Nov.
- P press release 1. 2023 Dec. Available from: Www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r
- Press release Roche 17. 2024 Jul.
- Press release Novo Nordisk A/S 20. 2024 Dec.
- E Lilly Press release 4. 2024 Dec.
- Viking therapeutics press release. 2023 Oct 17.
- Viking-Therapeutics press release. 2024 Feb 27.
- Viking Therapeutics press release 4. 2024 Nov.
- Carmot therapeutic press release 15. 2024 May.
- Amgen press release 26. 2024 Nov.
- Altimmune press release. 2023 Jun.
- Altimmune press release. 2023 Sep.
Cited by
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Rosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 129
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 48
Sallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 21
Cholecystokinin: Clinical aspects of the new biology
Rehfeld, J. F. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20110 · Cited by 11
“…and glucose-dependent insulinotropic polypeptide (GIP), from which several drugs have already been derived and used widely in the treatment of diabetes and obesity, with additional candidates in the pipeline and potential for therapy of cardiovascular, renal, and cerebral diseases as well [2–4].”
Metadata
- Authors
- Madsbad, S., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Madsbad, Sten
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2025-03
- Volume
- 34
- Issue
- 3
- Pages
- 197-215
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W4408078695
- Cited by
- 43
- References
- 122
- Citations by year
- 2026: 27 · 2025: 16
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity treatment, semaglutide, tirzepatide, liraglutide, cagrilintide, retatrutide, GIP/GLP-1 dual agonist, nonalcoholic steatohepatitis, weight loss maintenance, gastrointestinal adverse effects
- MeSH terms
- Liraglutide, Drug Development, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Glucagon-Like Peptides, Humans, Obesity, Weight Loss, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. https://app.cochat.ai/papers/10.1080/13543784.2025.2472408
- The paper
- Madsbad, S., & Holst, J. J. (2025). The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2025.2472408
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.